Advancing Rare Disease Research and the Development of Targeted Therapies

Michael Pourdehnad, MD, senior vice president, head of early clinical development, hematology/oncology & cell therapy at Bristol Myers Squibb discusses the work his team is doing at the site-level with potential oncology, hematology, and cardiovascular therapies. He also explores the area of targeted protein degradation and its evolution as well as his passion for bringing therapies to patients and how it shaped his career path.